Biotechnology — US PTAB Patent Cases
40 decisions indexed
Page 2 of 2 · 40 total
Curio Bioscience, Inc. v.Prognosys Biosciences Inc. et al.
The PTAB denied Curio Bioscience's IPR challenge against Prognosys and 10X Genomics, finding no reasonable likelihood of prevailing on grounds of anticipation (102), obviousness (103), or written description (112). The Board upheld the validity of the challenged claims in spatial omics/assay systems technology.
Curio Bioscience, Inc. v.Prognosys Biosciences Inc. et al.
The PTAB denied Curio Bioscience's IPR against Prognosys/10X Genomics, finding no grounds for invalidity based on obviousness (Cantor/Armani) or anticipation (Frisen). The Board concluded that the prior art did not teach the necessary combination elements of spatially encoded biological assays.
Curio Bioscience, Inc. v.Prognosys Biosciences Inc. et al.
The PTAB denied Curio Bioscience's IPR challenge against Prognosys and 10X Genomics, finding that the asserted claims were not obvious or anticipated by the prior art. The Board specifically rejected arguments linking Cantor to spatial analysis in tissue sections.
Curio Bioscience, Inc. v.Prognosys Biosciences Inc. et al.
Curio Bioscience, Inc.'s IPR challenge against Prognosys and 10X Genomics was denied by the PTAB. The Board found that Petitioner failed to demonstrate a reasonable likelihood of prevailing on grounds of obviousness (over Cantor/Armani) and anticipation (by Frisen).
Ajinomoto Co., Inc. v.AbTis Co., Ltd.
Ajinomoto Co., Inc. successfully convinced the PTAB to institute an IPR against AbTis Co., Ltd.'s patent (11896675) covering Antibody-Drug Conjugates (ADCs). The Board found sufficient evidence for institution on multiple grounds of anticipation and obviousness regarding claim 11.
NeoGenomics Laboratories, Inc. v.Natera, Inc.
NeoGenomics challenges Natera's patent covering cell-free DNA analysis methods in an IPR petition. The petitioner asserts that the claimed method is anticipated or obvious over multiple prior art references, including Forshew and Pieprzyk/May.
Illumina, Inc. v.Molecular Loop Biosciences, Inc.
Illumina Inc. has filed a petition challenging eight claims related to Next-Generation Sequencing (NGS) technology at the PTAB. The core argument is that the challenged methods are obvious over combinations of prior art, specifically involving dual-indexing techniques and sequencing platform substitutions. This challenge targets fundamental aspects of NGS methodology.
Illumina, Inc. v.Molecular Loop Biosciences, Inc.
Illumina filed an Inter Partes Review petition challenging Molecular Loop Biosciences' patents covering dual-indexing in Next-Generation Sequencing (NGS). The petitioner argued the claims were anticipated or obvious over prior art references like Gloor and Parameswaran. The PTAB decided to institute the IPR because the Examiner failed to consider relevant prior art during prosecution.
Bio-Rad Laboratories, Inc. v.California Institute of Technology et al.
Bio-Rad Laboratories filed a Petition challenging the obviousness of nine claims in patent 10068051, which relates to molecular diagnostics/PCR methods. The petitioner argues that the claimed multiplexed detection techniques are straightforward extensions of existing prior art concepts found in references like Saxonov and Silverbrook.
Bio-Rad Laboratories, Inc. v.California Institute of Technology et al.
Bio-Rad Laboratories has filed an IPR challenging the validity of a patent covering multiplex digital PCR assays owned by California Institute of Technology et al. The petitioner argues that the claimed methods are unpatentably obvious, representing only a straightforward extension of existing nucleic acid analysis concepts.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.